May 15th 2024
Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
The Utility of Molecular Testing in Colorectal Cancer: The Promise Needs Progress
February 15th 2014Molecularly profiling colorectal cancer has opened many potential opportunities for the use of this information in therapeutic decision-making. However, at present, only RAS testing in the metastatic setting has a definitive place in the decision-making paradigm.
Perioperative Chemotherapy for Colorectal Cancer Liver Metastases
November 15th 2013There is limited data available to guide decision making in the management of colorectal liver metastases. Despite a trend toward increased use of perioperative chemotherapy, others have questioned the role of this approach in patients with solitary lesions and a longer disease-free interval.
Colorectal Cancer Patients With Oligometastatic Liver Disease: What Is the Optimal Approach?
November 15th 2013In a good percentage of patients who have oligometastatic disease confined to a single organ-usually the liver-complete metastasectomy can result in cure. However, once the decision to pursue surgery is made, there remain a number of issues that must be addressed in order to ensure the best possible outcome.
PSA Screening in Men Newly Diagnosed With Colorectal Cancer: Each According to His Group’s Means?
October 15th 2013Once a patient has been appropriately educated by an informed healthcare provider about the possible benefits of PSA screening, then patient preference as part of shared decision making regarding PSA screening should be considered in all cases.
PSA Screening for Colorectal Cancer Patients: Proceeding With Caution
October 15th 2013It may be appropriate to offer prostate cancer screening to carefully selected men with a previous history of colorectal cancer. However, the risks and benefits of establishing the diagnosis in this setting need to be considered and discussed with them.
Should All Colorectal Cancer Patients Over Age 60 Be Screened for Prostate Cancer?
October 15th 2013Not all patients with colorectal cancer are candidates for such screening, however, as a remaining life expectancy of at least 10 years is generally required in order for PSA screening to yield a significant mortality benefit.
Early Tumor Shrinkage in Colorectal Cancer Suggests Long-Term Cetuximab Benefit
September 27th 2013Colorectal cancer patients who have early tumor shrinkage after first-line treatment with chemotherapy plus cetuximab may be more likely to have long-term response to therapy, according to an analysis of two large clinical trials.
Impact of Screening on Early- and Late-Stage Colorectal Cancers
September 22nd 2013A study on screening colonoscopy for colorectal cancers, originally presented at ASCO 2013, found that from 1976 to 2009 late-stage cancer incidence decreased from 117 to 74 cases per 100,000 people, and early-stage incidence decreased from 77 to 68 cases per 100,000.